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ABSTRACT Methods for the direct chiral chromatographic separation of the four
stereoisomers of meta-hydroxyphenylpropanolamine (MHPA) on an analytical and pre-
parative scale are described. Separations were carried out on a Crownpak CR (+) chiral
column with 113 mM aqueous perchloric acid as the mobile phase. Baseline resolution
of the more retained (+)-stereoisomers (1S configuration) and partial resolution of the
less retained (−)-stereoisomers (1R configuration) were obtained under these chromato-
graphic conditions. Removal of the bulk of the (1R,2S)-stereoisomer (metaraminol) from
the initial crude mixture by fractional crystallization as the (+)-bitartarate salt substan-
tially improved the peak resolution factors (Rs) of the remaining three stereoisomers.
Semipreparative chromatographic resolution of the latter isomeric mixture provided
milligram quantities of each stereoisomer in >97% enantiomeric excess. Subsequent
recrystallization of their bitartarate or fumarate salts gave enantiomeric purities >99%.
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Radiolabeled biogenic amines have achieved widespread
utility as neuronal markers for monoaminergic neurons. In
recent years, a variety of derivatives labeled with either
carbon-11 or fluorine-18 have been developed as positron
emission tomography (PET) radiotracers for in vivo stud-
ies of the peripheral noradrenergic neuronal system.1–5
Studies in our laboratory have focused on the synthetic
norepinephrine analog metaraminol (1a; Fig. 1), a clini-
cally used vasopressor.6 Metaraminol was shown to accu-
mulate in sympathetic nerve endings upon systemic
administration.6,7 We subsequently synthesized carbon-11-
labeled N-methylmetaraminol ([C-11]metahydroxy-
ephedrine, [C-11]HED) by direct N-methylation of com-
mercially available metaraminol with [C-11]CH3I for use as
a PET radiotracer for mapping sympathetic neurons.8 PET
studies with [C-11]HED have allowed noninvasive assess-
ment of the integrity of the human cardiac sympathetic
nervous system in the normal and transplanted heart, as
well as in disease states such as acute myocardial infarc-
tion and diabetic neuropathy.9–12
Metaraminol [(−)-(1R,2S)-1-(m-hydroxyphenyl)-2-amino-
1-propanol], is one of four possible stereoisomers (two ra-
cemic diastereomers: erythro and threo, respectively) of
meta-hydroxyphenylpropanolamine (MHPA; Fig. 1). As
part of a program aimed at evaluating the neuronal map-
ping potential of the remaining three stereoisomers of
[C-11]HED, we required convenient access to enantiomeri-
cally pure, milligram quantities of their corresponding
MHPA stereoisomers for carbon-11 labeling. Although a
two-step synthetic route for the conversion of metaraminol
to the (1S,2S)-stereoisomer (1d) has been reported in the
literature,13 the latter and remaining two stereoisomers
(1b, 1c) of MHPA are currently unavailable from commer-
cial sources. In this report, we describe a chiral chromato-
graphic method for the direct optical resolution of the four
individual MHPA stereoisomers and their corresponding
physical and spectral properties.
MATERIALS AND METHODS
Chemicals
Dowext 50W-X8 cation-exchange resin (400 mesh,
strongly acidic) and all chemical reagents were obtained
from Aldrich Chemical Co. (Milwaukee, WI). Absolute
ethanol was obtained from Midwest Grain Products of Illi-
nois (Pekin, IL). Metaraminol (1a), was purchased from
Sigma Chemical Co. (St Louis, MO). An analytical sample
of (±)-threo-MHPA (1c, 1d) as the naphthalene hemisulfo-
nate salt was kindly provided by Sterling Winthrop Re-
search Institute (Rensselaer, NY).
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General Instrumentation
1H NMR spectra were obtained in CD3OD on a Bruker
WM-360 (360 MHz) instrument with tetramethylsilane
(TMS) as internal standard. Mass spectra were obtained
on a Finnigan 4021 GCMS/DS (low resolution) or a UG70-
250-S (high resolution) instrument. Optical rotations were
measured at 589 nm in a 1 ml quartz microcell of 1 dm
optical pathlength using a Perkin-Elmer (Norwalk, CT) 241
polarimeter and c is expressed in g/100 mL. Melting points
were determined in open capillary tubes using a Thomas
Hoover melting point apparatus and are uncorrected.
Chromatography
The HPLC system consisted of a Beckman (Palo Alto,
CA) Model 421 controller, Model 112 pump, a Rheodyne
7161 injector equipped with a 1.0 ml sample loop, and an
Applied Biosystems (Foster City, CA) Model 757 UV vari-
able wavelength absorbance detector interfaced with a Wa-
ters (Rochester, MN) Model 740 electronic integrator. Mo-
bile phase solutions were prepared using distilled deion-
ized water from a Milli-Q system (Millipore, Bedford, MA)
and filtered through a 0.45-µm filter prior to use. All chro-
matographic procedures were conducted at ambient tem-
perature.
Analytical chromatography was carried out on a Crown-
pak CR (+) column (150 × 4 mm i.d., 5 µm; Daicel Chemical
Industries, Tokyo, Japan) using 113 mM aqueous perchlo-
ric acid (pH 1) as mobile phase at a flow rate of 0.5 ml/min
with UV detection at 254 nm. Samples for injection were
dissolved in the mobile phase and filtered through a 0.45-
µm filter prior to use. Analytical runs with either the au-
thentic standards or the crude mixture of stereoisomers
were conducted using 10–25-µl injections from a 1 mg/ml
stock solution.
Preparative chromatography was conducted using a 150
× 10 mm i.d. Crownpak CR (+) column at a flow rate of 2
ml/min with UV detection at 290 nm. Separations were
conducted with 60-µl injection volumes from a 100 mg/ml
stock solution of Mixture B. For each run, approximately
ten 1 ml fractions were collected during elution of the first
three components (1c, 1a, 1d) followed by five 2 ml frac-
tions during the elution of 1b. Fractions were reinjected on
the analytical system for confirmation of their optical pu-
rity. The limit of detection for each stereoisomer was ap-
proximately 0.1% (peak area) at a signal-to-noise ratio of 4.
Chromatographic Parameters
The capacity factors (k8) were calculated using the equa-
tion k8 = (tR-t0)/t0 where tR is the elution time and t0 is the
elution time for an unretained sample. The t0 for the ana-
lytical column was 3.6 min at a flow rate of 0.5 ml per min
as determined by injection of 1,3,5-tri-tert-butylbenzene as
the unretained standard. Elution times are the average of
triplicate determinations. Peak resolution (Rs) and separa-
Fig. 1. Stereoisomers of meta-hydroxyphenylpropanolamine (MHPA).
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tion (a) factors were calculated for each critical pair (clos-
est eluting pair of stereoisomers) as previously de-
scribed.14
Synthesis of MHPA Stereoisomers
A mixture containing the four stereoisomers of MHPA
was synthesized from propiophenone in 20% overall yield
using published procedures.15,16 (+)-(1S,2S)-MHPA (1d)
was also synthesized from metaraminol by an alternate
route, as previously described13 for use as an analytical
standard. All compounds had satisfactory physical and
spectral properties (1H NMR, mass spectral data).
Isolation of Metaraminol (1a) from MHPA
Isomeric Mixture
Two grams of the MHPA isomeric mixture (Mixture A)
was treated with a solution of (+)-(2R,3R)-tartaric acid (1.7
g, 11.3 mmoles) in 25 ml of hot 95% EtOH. The mixture was
heated to boiling and filtered to remove a small quantity of
an insoluble white residue. Crystallization commenced at
ambient temperature after concentration of the mixture to
a volume of approximately 20 ml. The mixture was stored
at −20°C overnight and filtered to provide 720 mg of the
(+)-bitartarate salt of metaraminol (1a) having a 95% enan-
tiomeric excess (ee) by chiral HPLC analysis. Concentra-
tion and cooling of the filtrate provided an additional 270
mg of 1a of approximately 92% ee. The combined products
were recrystallized three times from EtOH to provide 1a
with >99% optical purity. Concentration of the original
mother liquor (Mixture B) gave a brown gummy residue
(2.5 g) which was dissolved in water (10 ml) and converted
to the free base by cation-exchange chromatography (see
below) using approximately 15 g of resin.
Isolation of Free Base Forms of Individual MHPA
Stereoisomers by Cation-Exchange Chromatography
Five grams of Dowext 50W-X8 resin was rinsed with
ethanol (3 × 10 ml) until the eluant was clear. The wet resin
was introduced into a glass chromatography column (2 cm
i.d.) and eluted with deionized water (3 × 20 ml) until the
pH of eluant was equal to that of pure deionized water (pH
5.5–6.0). The pooled HPLC eluant fractions containing the
pure MHPA stereoisomer were then eluted through the
resin column with a low positive air pressure (2–3 psi) and
the resin was rinsed once more with deionized water until
eluant pH range was between 5.5 and 6.0. Elution with 30
ml of 4N ethanolic ammonia (NH4OH:EtOH; 35:65) and
concentration of the eluate under reduced pressure at
40°C afforded the stereoisomer as the free base. The latter
were obtained as amorphous solids by successive tritura-
tion of the residue with absolute EtOH and dry ethyl ether.
(−)-(1R,2S)-1-(m-hydroxyphenyl)-2-amino-1-propanol
(1a) Treatment of the free base with an equivalent por-
tion of (+)-(2R,3R)-tartaric acid and recrystallization from
EtOH provided the (+)-bitartarate salt: mp 175–177°C
(dec) (lit.17 176–177°C); [a]25D for HCl salt = −21° (c = 0.1,
H2O) {lit.17 [a]25D = −19.75°}; 1H NMR (free base in
CD3OD) d 7.15 (t, 1H), 6.81 (m, 2H), 6.70 (d, 1H), 4.37 (d,
1H, J = 5.62 Hz), 4.90 (s, 4H), 3.00 (dq, 1H, J = 6.13 Hz),
1.05 (d, 3H, J = 6.46 Hz); high resolution MS (DCI with
NH3) m/z 168.1020 (C9H14NO2 [M+H+] requires
168.1024).
(+)-(1S,2R)-1-(m-hydroxyphenyl)-2-amino-1-propanol
(1b) The free base was treated with (−)-(2S,3S)-tartaric
acid as described above and the (−)-bitartarate salt recrys-
Fig. 2. Chromatograms showing relative enantiomeric composition of
MHPA stereoisomers: in crude synthetic product mixture (Mixture A), in
mother liquor (Mixture B) after selective removal of (−)-metaraminol (1a)
by fractional crystallization. See text for experimental details.
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tallized from EtOH to provide an analytical sample: mp
175–177°C (dec) (lit.18 179–181°C); [a]25D = +5° (c = 0.1,
H2O) {lit.18 [a]25D = +4.4° (c = 1, H2O)}. The 1H NMR and
mass spectral data corresponded with that reported for the
(1R,2S) isomer above.
(−)-(1R,2R)-1-(m-hydroxyphenyl)-2-amino-1-propanol
(1c) The fumarate salt was prepared from the free base
and recrystallized from CH3OH:EtOAc (1:3) to provide an
analytical sample: mp 210–212°C (dec)(lit.13 208.2–
209.7°C); [a]25D = −32° (c = 0.1, H2O) {lit.13 [a]25D = −28°
(c = 2, H2O)}. 1H NMR (free base in CD3OD) d 7.14 (t, 1H),
6.78 (m, 2H), 6.69 (d, 1H), 4.16 (d, 1H, J = 7.54 Hz), 4.90 (s,
4H), 2.96 (dq, 1H, J = 6.82 Hz), 0.90 (d, 3H, J = 6.61 Hz);
high resolution MS (DCI with NH3) m/z 168.1022
(C9H14NO2 [M+H+] requires 168.1024).
(+)-(1S,2S)-1-(m-hydroxyphenyl)-2-amino-1-propanol
(1d) The free base was converted to the fumarate salt
and recrystallized from CH3OH:EtOAc (1:3) to give an ana-
lytical sample: mp 207–208°C (dec) (lit.13 206–209°C);
[a]25D = +31° (c = 0.1, H2O) {lit.13 [a]25D = +26° (c = 2,
H2O)}. The 1H NMR and mass spectral data corresponded
with that reported for the (1R,2R) isomer above.
RESULTS AND DISCUSSION
Prior approaches for preparation of the individual MHPA
stereoisomers used either fractional recrystallization17,18 of
the diastereomeric salts of tartaric acid (erythro series) or
chemical methods13 (threo series). In our hands, these
methods afforded both low product yields and optical pu-
rities (as determined by chiral HPLC analysis). The com-
plexity of the previously described methods and the need
for high optical purity prompted us to develop a chromato-
graphic approach for the direct isolation of the individual
MHPA stereoisomers.
Recent developments in chiral stationary phase (CSP)
technology have allowed direct chromatographic resolu-
tion of a wide variety of racemic compounds without the
need for prior derivatization. In particular, crown ether-
based CSP systems (e.g., Crownpak CRt), have demon-
strated superior ability at chiral resolution of primary
amine group-containing compounds such as amino acids
and amino alcohols.19 Isomer separation in these chiral
selectors is attributed to a preferential inclusion of the pro-
tonated amino group of one enantiomer in the crown ether
(18-crown-6) pocket.19 Thus, enantiomers forming less
stable complexes with the chiral crown ether elute prior to
those forming more stable complexes. The presence of the
amino alcohol functionality in MHPA led us to investigate
its chromatographic behavior in this CSP system.
A mixture of all four MHPA stereoisomers was synthe-
sized in 20% overall yield by a seven-step route15,16 using
propiophenone as starting material. The presence of the
(±)-erythro (1a, 1b) and (±)-threo (1c, 1d) enantiomeric
pairs in the crude product was confirmed by their charac-
teristic benzylic proton coupling constants of 5.6 and 7.5
Hz, respectively, in the 1H NMR spectrum. Integration of
the benzylic proton peak areas showed a 3:1 concentration
ratio for the (1a, 1b) and (1c, 1d) enantiomeric pairs,
respectively.
Analytical chiral HPLC analysis of the isomeric mixture
was conducted using a Crownpak CR (+) chiral column as
shown in Figure 2 (Mixture A). Elution of all four stereo-
isomers was complete within a 17-min period after injec-
tion. The identity of each stereoisomer was confirmed by
co-injection of the MHPA stereoisomeric mixture with the
available analytical standards. Under these conditions, the
(−)-enantiomers (1R configuration) elutes before the (+)-
enantiomers (1S configuration) in the following increasing
order of elution: (−)-threo (1c), (−)-erythro (1a), (+)-threo
(1d), and (+)-erythro (1b), respectively. The chromato-
graphic parameters obtained in this system are presented
in Table 1. Baseline resolution was obtained for the (+)-
stereoisomers (1b, 1d), whereas the (−)-stereoisomers
(1a, 1c) were only partially resolved under these condi-
tions. The relative HPLC peak areas of the erythro-to-threo
diastereomeric products was approximately 3:1, in agree-
ment with their concentration ratios obtained by 1H NMR
analysis.
Inspection of the elution profile of the MHPA stereoiso-
mers suggested that the chromatographic resolution of the
desired 1b, 1c, and 1d stereoisomers could be consider-
ably improved by reducing the concentration of 1a in the
mixture. This was accomplished by fractional crystalliza-
tion of a major proportion of 1a from the initial mixture as
its (+)-bitartarate salt. Thus, the isolation of two such crops
of 1a crystals resulted in a 4-fold decrease in its concen-
tration in the mother liquors, as indicated by HPLC analy-
sis (Fig. 2, Mixture B). In addition, improved resolution
factors (Rs) of 1.58, 1.74 and 2.84 were obtained for the
critical pairs (1a, 1c) (1d, 1a) and (1b, 1d), respectively.
The relative composition of each MHPA stereoisomer in
the mixture before (Mixture A) and after selective removal
of 1a (Mixture B) is shown in Table 2.
Preparative separation of a 120 mg sample of Mixture B
was carried out on a semipreparative Crownpak CR (+)
column by repeated injections of 6 mg portions of the mix-
ture. UV absorbance was monitored at 290 nm to attenuate
peak absorbance intensity. As the separation was con-
ducted under column overload conditions, typically smaller
TABLE 1. Chromatographic parameters for MHPA stereoisomers in Mixture A
Stereoisomer 1c 1a 1d 1b
Capacity factor (k8) 2.06 2.22 2.61 3.32
Separation factor (a) 1.08 1.17 1.27
(Critical pair) (1a, 1c) (1d, 1a) (1b, 1d)
Resolution (Rs) 0.92 1.57 2.35
(Critical pair) (1a, 1c) (1d, 1a) (1b, 1d)
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fractions (1 ml) were collected during elution of the initial
three components, followed by larger fractions (2 ml) dur-
ing elution of the more resolved final component, 1d. The
optical purity of the fractions was confirmed by reinjection
on the analytical system. Impure fractions were pooled,
concentrated, and reinjected. Appropriate high purity frac-
tions were combined and subjected to cation exchange
chromatography to afford 1c (15 mg; 98% ee), 1d (14 mg;
97% ee), and 1b (65 mg; 98% ee), respectively, as the free
base. Conversion to their respective bitartarate or fumarate
salts and subsequent recrystallization provided optical pu-
rities >99%. The final products were fully characterized
with respect to their physical (melting point, optical rota-
tion) and spectral (NMR, mass spectra) properties.
It has been reported that decreasing the column operat-
ing temperature improves the separation factor (a) in
these CSP systems.19 Optimization of column temperature
could therefore lead to further improvements in peak reso-
lution and separation factors which would permit the injec-
tion of larger sample sizes. Furthermore, it may be possible
to improve the purity of the individual fractions and also
reduce the total number of fractions collected by inclusion
of an in-line polarimeter in the system.
In conclusion, a sensitive chiral HPLC method for direct
and rapid analysis of all four stereoisomers of MHPA is
reported. This method is also sufficiently sensitive for the
preparative isolation of milligram quantities of these iso-
mers. Studies describing the carbon-11 labeling of these
stereoisomers and their biological evaluation will be re-
ported shortly.
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